AzTrials
AzTrials

Chronic Inflammatory Rheumatic Diseases of ChildhoodBOOST-RNCT07469787

Compassionate Care and Organization of Healthcare Services for a Successful Transition in Rheumatology

An observational study of Chronic Inflammatory Rheumatic Diseases of Childhood and Juvenile-Onset Chronic Inflammatory Rheumatic Diseases, run by Assistance Publique - Hôpitaux de Paris at 1 site in France.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record

Search all trials

Trial summary

The transition from pediatric to adult care is a critical period for young people with chronic inflammatory rheumatic diseases (CIRD) and is associated with risks of poor self-management, loss to follow-up, and disease worsening. Read more about this study

Who is it for?
Ages 18 years and older
How many people
50 participants
Where
1 siteFrance
Study dates
26 Feb 2026to 26 Aug 2027
Phase
Observational

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: Young adults with a diagnosis of chronic inflammatory rheumatic disease previously followed in pediatric rheumatology, who transitioned to adult care after participating in a joint pediatric-adult transition consultation at Bicêtre Hospital between 2018 and 2024.

Who may be able to join

  • Age 18 years or older
  • Diagnosis of chronic inflammatory rheumatic disease
  • Previously followed in pediatric rheumatology at Bicêtre Hospital
  • Participation in a joint pediatric-adult transition consultation between 2018 and 2024
  • Affiliated with a health insurance system
  • No objection expressed to participation after being informed about the study

Who cannot join

  • Patient lost to follow-up
  • No participation in a joint pediatric-adult transition consultation
  • Patient under guardianship, curatorship, or legal protection

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Perrine DUSSER, MD PhD contact

145213146 ext. 0033

perrine.dusser@aphp.fr

France1 site, 1 recruiting
  • CHU Bicêtre

    Le Kremlin-Bicêtre

    Perrine DUSSER, MD PhD, 145213146 ext. 0033, perrine.dusser@aphp.fr

    Recruiting

Other trials in France

About this study

The transition from pediatric to adult care is a critical period for young people with chronic inflammatory rheumatic diseases (CIRD) and is associated with risks of poor self-management, loss to follow-up, and disease worsening. Although structured transition programs have been recommended, real-world data on their effectiveness in rheumatology remain limited.

Since 2018, a structured transition program has been implemented at Bicêtre University Hospital (AP-HP, France), combining early transition preparation, a therapeutic patient education (TPE) workshop, and a joint pediatric-adult transition consultation. Some patients benefit from both components, while others receive a transition consultation only.

Read more

The BOOST-R study is a monocentric, non-interventional observational study designed to evaluate the impact of different transition modalities on self-management after transfer to adult care. The primary objective is to compare transition readiness, assessed using the validated French version of the Transition Readiness Assessment Questionnaire (TRAQ-FR), between patients who received a TPE workshop plus a transition consultation and those who received a transition consultation only.

Secondary objectives include evaluating continuity of care after transition, identifying factors associated with successful transition, assessing the contribution of the RESRIP support network, and describing patients who did not benefit from structured transition support.

Read the detailed description

The transition from pediatric to adult healthcare services represents a vulnerable period for adolescents and young adults with chronic inflammatory rheumatic diseases (CIRD). This phase is associated with increased risks of poor treatment adherence, disruption of follow-up, and adverse disease outcomes. While structured transition programs have been shown to improve patient autonomy and continuity of care, evidence in rheumatology remains limited, particularly regarding real-life effectiveness after transfer to adult care.

At Bicêtre University Hospital (AP-HP, France), a structured transition program has been progressively implemented since 2018 in collaboration with adult rheumatology and internal medicine departments. This program includes early transition information, progressive empowerment, a therapeutic patient education (TPE) workshop (MIRAJE program), and a joint pediatric-adult transition consultation. In parallel, some patients benefit from additional educational and administrative support provided by the RESRIP network after transition.

The BOOST-R study is a monocentric, observational, non-interventional study conducted in the pediatric rheumatology department of Bicêtre University Hospital. Adult patients with a diagnosis of CIRD who were followed in pediatric rheumatology and participated in a joint pediatric-adult transition consultation between 2018 and 2024 are eligible. Patients are contacted by postal mail and invited to complete an online questionnaire after receiving study information and having the opportunity to express non-opposition.

The primary outcome is transition readiness assessed using the French validated 20-item Transition Readiness Assessment Questionnaire (TRAQ-FR). The primary analysis compares the mean total TRAQ-FR score between patients who benefited from a TPE workshop plus a transition consultation and those who received a transition consultation only. Higher TRAQ-FR scores indicate better self-management and readiness for adult care.

Secondary outcomes include indicators of continuity of care after transition, such as number of adult care visits, delay to first adult visit, treatment adherence, and disease flares. Additional analyses will explore demographic, clinical, social, and educational factors associated with successful transition, evaluate the impact of support by the RESRIP network, and describe patients who did not benefit from structured transition interventions.

Statistical analyses will include descriptive analyses and multivariable regression models adjusted for relevant confounders, including age, sex, underlying disease, socio-professional status, and time since transition. Sensitivity analyses using propensity score methods will be performed to account for the non-randomized design.

The study involves no intervention and no additional risk for participants. Data are collected and managed in accordance with applicable French and European data protection regulations.

Keywords
Continuity of care, Therapeutic patient education, Self-management, Transitional care, Pediatric to adult transition, Chronic inflammatory rheumatic diseases

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Transition Readiness Assessment Questionnaire - French Version (TRAQ-FR) Total Score

    Total score of the Transition Readiness Assessment Questionnaire - French version (TRAQ-FR).

    The TRAQ-FR is a validated self-administered questionnaire assessing transition readiness in adolescents and young adults with chronic disease. It includes 20 items rated on a 5-point Likert scale (1-5).

    The total score is calculated as the mean of completed items. Score range: 1 to 5. Higher scores indicate greater transition readiness (better outcome).

    Measured: Baseline (at the time of questionnaire completion in 2026, corresponding to 1 to 8 years after transition depending on individual transition date)

Secondary outcomes (5)
  1. Transition Readiness Assessment Questionnaire - French Version (TRAQ-FR) Domain Scores

    Domain-specific scores of the TRAQ-FR, including: Medication management, Appointment keeping, Tracking health issues, Communication with healthcare providers, Managing daily activities, Each domain score is calculated as the mean of completed items within that domain.

    Score range for each domain: 1 to 5. Higher scores indicate greater transition readiness.

    Measured: Baseline (at the time of questionnaire completion in 2026)

  2. Continuity of adult care within 12 months after transition

    Proportion of patients who attended at least one adult specialist consultation within 12 months after their last pediatric visit.

    Unit of measure: Percentage (%). Higher percentage indicates better continuity of care.

    Measured: 12 months after transition

  3. TRAQ-FR Total Score according to participation in structured transition support programs

    Comparison of TRAQ-FR total score between patients who participated in a structured transition support program (therapeutic patient education and/or structured support network) and those who did not.

    Score range: 1 to 5. Higher scores indicate greater transition readiness.

    Measured: Baseline (at the time of questionnaire completion in 2026)

  4. Continuity of adult care according to participation in structured transition support programs

    Proportion of patients attending at least one adult specialist consultation within 12 months after transition, compared between patients with and without structured transition support.

    Unit of measure: Percentage (%).

    Measured: 12 months after transition

  5. Successful transition defined by TRAQ-FR total score ≥4

    Proportion of patients with a TRAQ-FR total score ≥4, considered indicative of high transition readiness.

    Unit of measure: Percentage (%). Higher percentage indicates more successful transition.

    Measured: Baseline (at the time of questionnaire completion in 2026)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted13 Mar 2026
  2. Study start26 Feb 2026
  3. Primary completion26 Aug 2027 (estimated)
  4. Study completion26 Aug 2027 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
50 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07469787
Sponsor's protocol ID
APHP251147
Other IDs
2025-A01787-42
Acronym
BOOST-R
Status last verified
Jan 2026
First submitted
9 Feb 2026
Last updated
21 Apr 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in